Today’s health care environment is marked by transition and uncertainty. Health care managers must regularly juggle multiple project initiatives with limited time and resources, which often means ...

Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...

COPENHAGEN, Denmark, December 29, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value ...

Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and ...